Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

“…The addition of R to conventional CHOP chemotherapy, either as induction or maintenance, has now been shown to improve outcome in patients with DLBCL. 8,22,23 Our findings suggest that this improvement in outcome may be primarily due to the beneficial effect of R added to CHOP in the Bcl-6 Ϫ subset of DLBCL.…”

Non-Hodgkin's Lymphomas

“…[281][282][283] Long-term follow-up of this study showed that progression-free (36.5% vs. 20%), disease-free (64% vs. 43%), and overall survival rates (43.5% vs. 28%) were statistically significant in favor of R-CHOP at a median follow-up of 10 years. 284 These findings have been confirmed in 3 additional randomized trials, including the MabThera International Trial (MInT; 6 cycles of R-CHOP or CHOP), which extended the findings to young patients with 0 or 1 risk factors according to the IPI 285,286 ; the Dutch HOVON and Nordic Lymphoma group study (8 cycles of R-CHOP-14 or CHOP-14); and the ECOG/CALGB study, which confirmed the findings in patients older than 60 years. 287,288 The ECOG/CALGB study also showed that maintenance rituximab significantly prolonged failure-free survival in older patients whose disease responded to CHOP chemotherapy, but it did not show any clinical benefit for those whose disease responded to R-CHOP as induction therapy.…”

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

“…Rituximab, a type I chimeric IgG1 anti-CD20 antibody, given alone or in combination with standard chemotherapy regimens, is associated with increased response rates and improved progression free-survival and overall survival with an acceptable safety profile. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15] Maintenance therapy with rituximab has been demonstrated to significantly improve responses and progression free-survival in both previously untreated and relapsed follicular lymphoma (FL). [16][17][18] However, indolent lymphomas, such as FL and chronic lymphocytic leukemia (CLL) remain incurable, with patients exhibiting relapses after each treatment, highlighting the need for more effective therapies.…”